0001567619-19-012607.txt : 20190603
0001567619-19-012607.hdr.sgml : 20190603
20190603173919
ACCESSION NUMBER: 0001567619-19-012607
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190530
FILED AS OF DATE: 20190603
DATE AS OF CHANGE: 20190603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DIVIS GREG J
CENTRAL INDEX KEY: 0001410677
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 19874497
MAIL ADDRESS:
STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4
1
doc1.xml
FORM 4
X0306
4
2019-05-30
0
0001012477
AVADEL PHARMACEUTICALS PLC
AVDL
0001410677
DIVIS GREG J
C/O AVADEL PHARMACEUTICALS PLC
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN
L2
15
IRELAND
0
1
0
0
Chief Executive Officer
ADSs
67100
D
Stock Option (right to buy)
10.4
2026-12-14
ADSs
150000
150000
D
Stock Option (right to buy)
8.95
2027-12-12
ADSs
100000
100000
D
Stock Option (right to buy)
7.06
2028-03-22
ADSs
50000
50000
D
Stock Option (right to buy)
1.85
2029-03-07
ADSs
100000
100000
D
Stock Option (right to buy)
1.71
2019-05-30
4
A
0
400000
0.00
A
2029-05-30
ADSs
400000
400000
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary).
Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 3/22/2018 grant date.
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date.
Options become exercisable as to 100,000 ADSs on each of the first four anniversaries after the 5/30/2019 grant date.
/s/ Phillandas T. Thompson as attorney in fact for Greg J. Divis
2019-06-03